Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

1.02

Mkt cap

6.9M

Volume

193K

High

1.09

P/E Ratio

-0.27

52-wk high

4.17

Low

1.00

Div yield

N/A

52-wk low

0.77

Adial Pharmaceuticals announced a peer-reviewed publication showcasing safety data and high patient compliance in a clinical trial of AD04, a potential treatment for alcohol disorder.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:00 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Longeveron (LGVN) led the gainers with a 75.0% increase, while BioRestorative Therapies (BRTX) experienced the largest drop among the losers, falling 18.8%. Other notable movers include PetVivo Holdings (PETV) and Ocugen (OCGN), which saw increases of 17.09% and 8.19%, respectively. On the downside, Supernus Pharmaceuticals (SUPN) and Virpax Pharmaceuticals (VRPX) saw declines of 16.34% and 11.32%, respectively.

Portfolio Pulse from Benzinga Insights

April 08, 2024 | 12:09 pm

In Friday's after-market session, several healthcare stocks showed notable movements. Longeveron (LGVN) led the gainers with a 48.6% increase, while Elicio Therapeutics (ELTX) experienced the largest decline among the losers, dropping 10.3%. Other notable movers included Adial Pharmaceuticals (ADIL), Etao International Co (ETAO), and Inovio Pharmaceuticals (INO) with significant gains, and SINTX Techs (SINT), Cerus (CERS), and MediciNova (MNOV) among the losers.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 8:31 pm

Adial Pharmaceuticals reported its FY23 cash and cash equivalents at $2.8 million as of December 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:37 pm

Cardlytics, Inc. (CDLX) shares surged by approximately 37% in pre-market trading after reporting Q4 earnings that exceeded expectations, with adjusted earnings of 14 cents per share against estimates of 12 cents. The company also forecasted Q1 revenue between $70 million and $73 million, surpassing the expected $66.46 million. Other stocks showed significant movement in pre-market trading, with notable gainers including Fisker Inc. (FSR), Madrigal Pharmaceuticals, Inc. (MDGL), and American Vanguard Corporation (AVD), among others. Conversely, companies like Kopin Corporation (KOPN), Smartsheet Inc. (SMAR), and Adobe Inc. (ADBE) experienced declines.

Portfolio Pulse from Avi Kapoor

March 15, 2024 | 12:13 pm

Adial Pharmaceuticals (NYSE:ADIL) has seen a significant increase in short interest, with the short percent of float rising 692.2% to 11.17%. This indicates a bearish market sentiment towards ADIL, although it doesn't necessarily predict a near-term price fall. Compared to its peers, ADIL has a higher short interest, suggesting more bearish sentiment than average within its peer group.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 8:15 pm

Traders are circulating unconfirmed analyst comments about Adial Pharmaceuticals (ADIL), suggesting that the company's management is in advanced discussions with a large pharma partner for the addiction marketplace in the U.S., EU, or both. The comments also include a buy rating with a $21 price target (PT).

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:13 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Quoin Pharmaceuticals, Ainos, and Helius Medical Tech were among the top gainers, with stock prices increasing by 71.1%, 69.52%, and 55.04% respectively. On the losing side, BioVie, First Wave BioPharma, and Sunshine Biopharma saw declines of 46.0%, 29.44%, and 21.49%. Notably, 89bio and Akili released their Q4 earnings reports two days ago, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 1:09 pm

BioVie Inc. shares fell by 41.8% in pre-market trading after announcing the pricing of a public offering. Other stocks showed significant movement in pre-market trading, with Ainos, Inc., MSP Recovery, Inc., and Jaguar Health, Inc. among the top gainers. Conversely, Adial Pharmaceuticals, Inc., Caledonia Mining Corporation Plc, and Minim, Inc. were among the top losers.

Portfolio Pulse from Avi Kapoor

March 04, 2024 | 1:04 pm

Zscaler, Inc. (ZS) shares fell by 10.1% following its Q2 earnings report, despite better-than-expected results. Other stocks showed significant movement, with BioVie Inc. (BIVI) and Adial Pharmaceuticals, Inc. (ADIL) among the top gainers. Losers included GigCapital5, Inc. (GIA) and Fisker Inc. (FSR), with FSR dropping 44.6% due to concerns about its going concern status.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 6:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.